





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : <b>C07K 5/00, 7/00, A61K 37/02</b>		<b>A1</b>	(11) International Publication Number: <b>WO 94/03479</b>
			(43) International Publication Date: 17 February 1994 (17.02.94)
(21) International Application Number: PCT/US93/06428 (22) International Filing Date: 8 July 1993 (08.07.93) (30) Priority data: 07/922,340                      30 July 1992 (30.07.92)                      US 08/080,788                      28 June 1993 (28.06.93)                      US (60) Parent Applications or Grants (63) Related by Continuation US                                      07/922,340 (CIP) Filed on                                      30 July 1992 (30.07.92) US                                      08/080,788 (CIP) Filed on                                      28 June 1993 (28.06.93) (71) Applicant (for all designated States except US): COR THER- APEUTICS, INC. [US/US]; 256 E. Grand Avenue, South San Francisco, CA 94080 (US).		(72) Inventor; and (75) Inventor/Applicant (for US only) : SCARBOROUGH, Ro- bert, M. [US/US]; 2544 Belmont Canyon Road, Bel- mont, CA 94002 (US). (74) Agent: HEINES, M., Henry; Townsend and Townsend Khourie and Crew, Steuart Street Tower, 20th Floor, One Market Plaza, San Francisco, CA 94105 (US). (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: THROMBIN RECEPTOR ANTAGONISTS



(I)



(II)

## (57) Abstract

Peptide derivatives serving as thrombin receptor antagonists are disclosed, which bear specificity for the cellular thrombin receptor without interfering with the catalytic activities of thrombin. The derivatives generally have formula (I) in which R<sup>1</sup> and R<sup>3</sup> are amide linkages, N-alkylamide linkages, or isosteric replacements of such linkages; R<sup>2</sup> is either a neutral amino acid side chain or a hydrophobic radical; R<sup>4</sup> is hydrophobic radical; R<sup>5</sup> is CO, CH<sub>2</sub> or SO; X is either of formula (II) in which R<sup>6</sup> and R<sup>7</sup> are H, alkyl, cycloalkylalkyl, alkoxyalkyl, alkylthioalkyl or arylalkyl, and R<sup>8</sup> is a hydrophobic radical, or a hydrophobic residue; Y is alkyl, hydroxy, amino, alkylamin, dialkylamino, in which any of the alkyl groups may be substituted with a basic moiety; Z is an amino acid or peptide residue; and m is zero or one.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

## THROMBIN RECEPTOR ANTAGONISTS

### BACKGROUND OF THE INVENTION

5           This invention relates to materials which modulate the action of thrombin on cells of the vascular and circulating blood system. It is well known that thrombin has multiple activities. Perhaps the most well known activity of this serine protease is to convert fibrinogen to fibrin which clots blood. Additional functions of thrombin are widespread and diverse and appear to involve cellular activations which are mediated  
10           through cellular thrombin receptor(s). For example, thrombin is the most potent activator of platelets; it is chemotactic for monocytes; it is mitogenic for lymphocytes and mesenchymal cells including vascular smooth muscle cells and; it promotes numerous responses within the vascular endothelium. See, Coughlin, et al., *J. Clin. Invest.* 89:351-355 (1992). Because these cell activating functions of thrombin occur within the range of  
15           concentrations normally required for the clotting of blood, thrombin has been proposed to play important physiological roles not only in hemostasis and thrombosis but may also have principle roles in mediating responses to vascular injury such as leukocyte chemotaxis to mediate inflammation, cellular proliferation to mediate restenosis, glomerulonephritis, and wound repair such as occurs in bone remodeling.

20           The role of thrombin in acute thrombosis has been clearly established. For a review, see, Chesbro et al., *Thromb. Haemostas.*, 66:1-5 (1991). However, thrombin's role in thrombosis is not limited to its blood clotting activity but also extends to platelet aggregation as thrombin appears to be the principle physiological mediator of platelet aggregate formation at sites of vascular injury resulting from the activation of the platelet  
25           thrombin receptor. Recent antithrombotic approaches inhibit or modulate the enzymatic activity of thrombin and include compounds such as heparin, low molecular weight heparins, PPACK, hirudins, argatroban, and the hirulogs. All of these agents inhibit the catalytic activity of the enzyme. Therefore, these agents not only inhibit the pro- and anticoagulant actions of thrombin but also the cell activating functions of thrombin as well.  
30           Accordingly, none of these agents are useful for specifically inhibiting the cellular actions of thrombin. No agent which specifically targets the thrombin receptor has been clinically developed. Previous attempts to identify a thrombin receptor inhibitor have been thwarted by the inability of researchers, until very recently, to identify the physiologically relevant and functional thrombin receptor.

35           Thrombin has numerous effects on a variety of cells outside of platelets.

For example, thrombin is mitogenic for smooth muscle and endothelial cells. Thrombin is also known to increase vascular permeability and to induce vasoconstriction. See, Malik, *Semin. Thromb. Hemostasis*, 12:184-196 (1986). Thrombin can also induce the production and release of several constituents from endothelial cells including platelet-derived growth factor (PDGF), prostacyclin, platelet-activating factor (PAF), tissue plasminogen activator and plasminogen activator inhibitor. Finally, thrombin is capable of promoting the adherence of platelets, neutrophils, monocytes and T cells. For review, see, Shuman, *Ann. NY Acad. Sci.* 485:228-239, (1986). All of these actions of thrombin are likely to be mediated by cellular thrombin receptors identical or nearly identical to the cloned thrombin receptor and suggest that thrombin may also play a central role in initiating inflammatory and cellular proliferative responses to vascular injury linking it with the coagulation and hemostasis cascades. While most of these responses to thrombin suggest such a linkage between hemostasis and vascular repair, this hypothesis remains to be tested. Agents which specifically effect the activation of thrombin receptor(s) within cells are ideally suited to this purpose.

Restenosis, the vascular hyperproliferative response to blood vessel wall injury induced by interventional procedures such as coronary angioplasty, may be stimulated by thrombin-induced cellular events as sites of injury either directly or indirectly. Cellular proliferation may be simulated indirectly by the release of potent growth factors from locally adherent platelets or by the action of thrombin on endothelial cells which could release PDGF upon stimulation. Smooth muscle cell proliferation within diseased vessels may also be stimulated directly by thrombin due to the high local concentration of thrombin generated at the vascular injury sites created by the active platelet-rich thrombus. Indeed, recent studies with the potent thrombin inhibitor hirudin suggest that thrombin plays such a role in the restenosis process, but it is not known for these studies whether thrombin's effect is direct or indirect. See, Sarembock, et al., *Circulation*, 84:232-243, (1992).

Although the cellular actions of thrombin have the potential for causing various pathological conditions, there are no known therapeutic agents which specifically block the cellular actions of thrombin. Recently, however, a functional thrombin receptor cDNA has been cloned and expressed from megakaryoblastic cells lines, and the presence of mRNA encoding this receptor has been demonstrated in human platelets and vascular endothelial cells. See, Vu, et al., *Cell*, 64:1057-1068 (1991). This development has created significant opportunities to develop highly specific agents which target the cellular thrombin receptor.

Close inspection of the predicted amino acid sequence of the thrombin receptor revealed a potential recognition and thrombin cleavage sequence within the 100-residue amino terminal domain of the receptor. Subsequent mutagenesis studies of the

receptor has demonstrated that this cleavage site is required for thrombin-mediated receptor signaling through proteolytic cleavage at this site. See, Vu, et al., *Nature*, 353:674-677 (1991). These experiments confirmed previous suggestions that proteolysis of a putative thrombin receptor might be responsible for thrombin receptor activation but left  
5 unanswerd how proteolysis mediates receptor signaling.

Two potential explanations for thrombin-induced signaling have been postulated. The first is that proteolytic removal of the 15-residue segment at the amino terminus of the receptor induces a conformational change in the receptor leading to receptor activation. Alternatively a specific "tethered ligand" sequence unmasked upon  
10 receptor proteolysis may directly interact with a "ligand binding site" within the body of the receptor leading to receptor activation. While both of these potential mechanisms are quite similar, if not semantic, it appears that the "tethered ligand" hypothesis is the more likely explanation for receptor signaling. Synthetic peptides which mimic the new amino acid sequence revealed upon receptor proteolysis function as full agonists of the platelet  
15 receptor even in the absence of proteolytic cleavage of the receptor. This suggests that the new amino acid sequence at the amino terminus of the receptor revealed upon cleavage of the receptor functions as a "tethered ligand" and interacts at a distal "binding site". These effects have been confirmed with the hamster receptor activated with the hamster "tethered ligand" peptide. See, Vouret-Craviari, et al., *Mol. Biol. Cell.* 3:95-102, (1992).  
20 Additional studies with agonist peptides have confirmed the similarity of putative thrombin receptors present in platelets, endothelial cells, fibroblasts and smooth muscle cells. See, Hung et al., *J. Cell. Biol.* 116:827-832, (1992) and Ngaiza and Jaffe, *Biochem. Biophys. Res. Commun.* 179:1656-1661 (1991).

Most research conducted to date on modulating the actions of thrombin have  
25 been directed toward non-specific inhibition of the catalytic activity of thrombin. These efforts have resulted in thrombin inhibitors which effect both the pro- and anti-coagulant actions of thrombin. For a review, see, Chesbro and Fuster, *Circulation*, 83:1815-1817 (1991). Certain investigators have also attempted to inhibit the cellular activities of thrombin by using polypeptides prepared from the sequence of thrombin. See, Carney and  
30 Glenn, International Patent Application Under the PCT, No. WO 88/03151, 5 May 1988. Another report has focused on the preparation of certain dipeptides and analogs which appear to inhibit thrombin-cellular activities without effecting the catalytic activity of thrombin. See, Ruda, et al., *Biochem. Pharmacol.* 39:373-381 (1990). Both of these approaches display a certain degree of specificity but are limited due to their lack of potent  
35 effects.

Structure-activity studies using the thrombin receptor agonist peptide sequences have also been reported. A pentapeptide sequence, Phe-Leu-Leu-Arg-Asn-OH, based on a portion of the agonist peptide minimum structure has been shown to be a weak

antagonist of platelet thrombin receptors activated with either thrombin or thrombin receptor agonist peptides. See, Vassallo, et al., *J. Biol. Chem.* 267:6081-6085 (1992).

5 A different approach to receptor antagonism has been investigated by others who have raised antibodies against a peptide sequence within the amino-terminal domain of the thrombin receptor which appears to be a binding/recognition site for thrombin. These antibodies effectively and specifically block thrombin-induced responses in platelets, thereby acting as antagonists of the thrombin receptor. See, Hung et al., *J. Clin. Invest.* 89:1350-1353 (1992).

10 The lack of potency and/or specificity of the above described approaches to thrombin receptor antagonism limits their utility as thrombin receptor antagonists. Thus, highly potent and specific inhibitors of the thrombin receptor are the focus of this invention.

### SUMMARY OF THE INVENTION

15 Peptide derivatives which act as potent and highly specific thrombin receptor antagonists have now been discovered. These antagonists exhibit specificity for the cellular thrombin receptor, which allows them to modulate cellular responses such as platelet aggregation without interfering with certain desired catalytic activities of thrombin, such as the conversion of fibrinogen to fibrin. These peptide derivatives include peptides and modified peptides which contain functional groups that enhance *in vivo* stability and  
20 therapeutic potential.

The peptide derivatives of the present invention bind to cellular thrombin receptors and inhibit the activation of the receptor induced by thrombin. Included among the thrombin receptor antagonists of the invention are small peptide derivatives and peptide analogs containing isosteric replacements for labile amide linkages. This preferred class of  
25 peptide derivatives offers an even greater improvement in therapeutic potential since the structure of peptide derivatives of this type renders them less susceptible to proteolytic inactivation.

The invention also resides in pharmaceutical compositions containing the peptide derivatives described above. These compositions are useful as anti-thrombotics  
30 and are also useful in clinical applications including treatment of abrupt closure during angioplasty, treatment of restenosis in the context of angioplasty, and the treatment of unstable angina, myocardial infarction and certain forms of thrombotic or thromboembolytic stroke. The peptide derivatives of the invention may be used alone or in combination with other therapeutic agents such as urokinase and tPA. These

compositions are also useful as anti-inflammatory, anti-restenosis agents and may be used to treat and/or prevent glomerulonephrotic syndromes.

## DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "alkyl" refers to a saturated hydrocarbon radical which may be straight-chain or branched-chain (for example, ethyl, isopropyl, *t*-amyl, or 2,5-dimethylhexyl). This definition applies both when the term is used alone and when it is used as part of a compound term, such as "aralkyl" and similar terms. Preferred alkyl groups are those containing 1 to 10 carbon atoms. All numerical ranges in this specification and claims are intended to be inclusive of their upper and lower limits.

The term "cycloalkyl" refers to a saturated hydrocarbon ring. Preferred cycloalkyl moieties are those having 3 to 8 carbon atoms in the ring. Additionally, the term "(cycloalkyl)alkyl" refers to a group having a cycloalkyl moiety attached to an alkyl moiety. Examples are cyclohexylmethyl, cyclohexylethyl and cyclopentylpropyl.

The term "alkenyl" as used herein refers to an alkyl group as described above which contains one or more sites of unsaturation.

The term "alkoxy" refers to an alkyl radical as described above which also bears an oxygen substituent which is capable of covalent attachment to another hydrocarbon radical (such as, for example, methoxy, ethoxy, phenoxy and *t*-butoxy).

The term "aryl" refers to an aromatic substituent which may be a single ring or multiple rings which are fused together, linked covalently or linked to a common group such as an ethylene or methylene moiety. The aromatic rings may each contain heteroatoms, for example, phenyl, naphthyl, biphenyl, diphenylmethyl, 2,2-diphenyl-1-ethyl, thienyl, pyridyl and quinoxalyl. The aryl moieties may also be optionally substituted with halogen atoms, or other groups such as nitro, carboxyl, alkoxy, phenoxy and the like. Additionally, the aryl radicals may be attached to other moieties at any position on the aryl radical which would otherwise be occupied by a hydrogen atom (such as, for example, 2-pyridyl, 3-pyridyl and 4-pyridyl).

The terms "arylalkyl", "arylalkenyl" and "aryloxyalkyl" refer to an aryl radical attached directly to an alkyl group, an alkenyl group, or an oxygen which is attached to an alkyl group, respectively.

The term "basic moiety" refers to a group which is capable of accepting a proton, or donating a pair of electrons in hydrogen bonding. Examples of basic moieties are amines, guanidines, imidates, and nitrogen-containing heterocycles such as pyridine, imidazole, triazole and pyrimidine.

The term "hydrocarbon radical" refers to alkyl, alkenyl, alkoxy or aryl

radical or any combination thereof.

The term "hydrophobic radical" refers to a group which lowers the water solubility of a molecule. Preferred hydrophobic radicals are groups containing at least 3 carbon atoms.

5 The terms "isostere" and "isosteric replacement" are used interchangeably to refer to groups which have similar electronic or spatial properties. In the context of the present invention, for example, —CONH— may be replaced by —CH<sub>2</sub>NH—, —NHCO—, —SO<sub>2</sub>NH—, —CH<sub>2</sub>O—, —CH<sub>2</sub>CH<sub>2</sub>—, —CH<sub>2</sub>S—, —CH<sub>2</sub>SO—, —CH=CH— (cis or trans), —COCH<sub>2</sub>—, —CH(OH)CH<sub>2</sub>— and 1,5-disubstituted tetrazole  
10 such that the radicals linked by these isosteres would be held in similar orientations to radicals linked by CONH. For a general review of these and other isosteres see, Spatola, A.F., in *Chemistry and Biochemistry of Amino Acids, Peptides and Proteins*, B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983).

15 The term "neutral amino acid side chain" refers to that portion of an amino acid which is attached to the carbon adjacent to the carbonyl and which has no formal charge at physiological pH. Examples of neutral amino acid side chains are hydroxymethyl (from serine) and mercaptomethyl (from cysteine).

For the compounds of the invention which contain amino acid or peptide fragments, the amino acid residues are denoted by single-letter or three-letter designations  
20 following conventional practices. The designations for gene-encoded amino acids are as follows:

	<u>Amino Acid</u>	<u>One-Letter Symbol</u>	<u>Three-Letter Symbol</u>
	Alanine	A	Ala
25	Arginine	R	Arg
	Asparagine	N	Asn
	Aspartic acid	D	Asp
	Cysteine	C	Cys
	Glutamine	Q	Gln
30	Glutamic acid	E	Glu
	Glycine	G	Gly
	Histidine	H	His
	Isoleucine	I	Ile
	Leucine	L	Leu
35	Lysine	K	Lys
	Methionine	M	Met
	Phenylalanine	F	Phe




5	Proline	P	Pro
	Serine	S	Ser
	Threonine	T	Thr
	Tryptophan	W	Trp
	Tyrosine	Y	Tyr
	Valine	V	Val

Commonly encountered amino acids which are not gene-encoded may also be used in the present invention. These amino acids and their abbreviations include ornithine (Orn); *t*-butylglycine (*t*-BuG); phenylglycine (PhG); cyclohexylalanine (Cha);  
 10 norleucine (Nle); 2-naphthylalanine (2-Nal); 1-naphthylalanine (1-Nal); 2-thienylalanine (2-Thi); 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic); N-methylisoleucine (N-Melle), homoarginine (Har), N $\alpha$ -methylarginine (N-MeArg) and sarcosine (Sar).

All of the amino acids used in the present invention may be either the D- or L-isomer. The L-isomers are preferred.

15 The compounds of the present invention bind to the thrombin receptor but will not activate it. These antagonists are represented by the formula:




20 The groups R<sup>1</sup> and R<sup>3</sup> in this formula are the same or different, each being either an amide linkage, an N-alkylamide linkage, or an isosteric replacement of these linkages.

The groups R<sup>2</sup> and R<sup>4</sup> are likewise the same or different, and each is a hydrophobic radical. Examples of hydrophobic radicals for these groups are phenyl, *t*-butyl, isopropyl, isobutyl, cyclohexylmethyl, 1-adamantylmethyl, cyclopentylmethyl, cycloheptylmethyl, benzyl, 4-hydroxybenzyl, 2-naphthylmethyl, 1-naphthylmethyl, 2-thienylmethyl, methylthioethyl, indolylmethyl, and substituted benzyl. In preferred  
 25 structures, either R<sup>2</sup> or R<sup>4</sup> is cyclohexylmethyl, or both are cyclohexylmethyl. In addition, R<sub>2</sub> is any amino acid side chain which does not carry a formal charge at physiological pH. Examples of neutral amino acid side chains are hydroxymethyl and mercaptomethyl.

The group R<sup>5</sup> is either CO, CH<sub>2</sub> or SO.

30 The symbol X represents a variety of structures. Some of these structures are represented by the formula:

8



(II)

in which  $\text{R}^6$  and  $\text{R}^7$  are the same or different, each being either H, alkyl, (cycloalkyl)alkyl, alkoxyalkyl, alkylthioalkyl or arylalkyl; and  $\text{R}^8$  is a hydrophobic radical. Preferred groups for  $\text{R}^6$  and  $\text{R}^7$  are H,  $\text{C}_1$ - $\text{C}_{10}$  alkyl, ( $\text{C}_1$ - $\text{C}_8$  cycloalkyl)-( $\text{C}_1$ - $\text{C}_4$  alkyl), ( $\text{C}_1$ - $\text{C}_{10}$  alkoxy)-( $\text{C}_1$ - $\text{C}_{10}$  alkyl), ( $\text{C}_1$ - $\text{C}_{10}$  alkylthio)-( $\text{C}_1$ - $\text{C}_{10}$  alkyl), aryl-( $\text{C}_1$ - $\text{C}_6$  alkyl), with the proviso that at least one of  $\text{R}^6$  and  $\text{R}^7$  is other than H. Preferred groups for  $\text{R}^8$  are those which are at least as hydrophobic as an isopropyl group. Particularly preferred are benzyl and phenethyl. Other structures for X are hydrophobic residues which contain aryl moieties. Preferred among these are arylalkyl, arylalkenyl, aryloxyalkyl, biphenyl, 1,2,3,4-tetrahydronaphthyl, indolylmethyl, quinoliny, isoquinoliny, 1,2,3,4-tetrahydroisoquinoliny, 1,2,3,4-tetrahydroquinoliny, N-alkyl and N-(cycloalkyl)alkyl 1,2,3,4-tetrahydroisoquinoliny, and N-alkyl 1,2,3,4-tetrahydroquinoliny. Specific examples of X groups which are hydrophobic residues containing aryl moieties are 1-phenyloct-1-en-2-yl, 1-phenoxy-1-propyl, 1-(2-naphthyloxy)-1-heptyl, 1-phenoxy-1-pentyl, 1-(1-naphthyloxy)-1-pentyl, biphenyl, 1-naphthyl, 2-naphthyl, 1,2,3,4-tetrahydronaphth-2-yl, indolylmethyl, 2-quinolyl, 3-quinoliny, N-pentyl-1,2,3,4-tetrahydroisoquinoliny, and N-cyclohexylmethyl-1,2,3,4-tetrahydroisoquinoliny.

Of the remaining groups, Y is an alkoxy, hydroxy, amino, alkylamino, dialkylamino, or a substituted alkoxy or alkylamino group. Preferred groups for Y are those having the formulas  $\text{OR}^9$  or  $\text{NR}^{10}\text{R}^{11}$  wherein  $\text{R}^9$ ,  $\text{R}^{10}$  and  $\text{R}^{11}$  are the same or different, each being either H,  $\text{C}_1$ - $\text{C}_{10}$  alkyl, or a hydrocarbon radical substituted with a basic moiety. Further preferred among these are  $\text{NR}^{10}\text{R}^{11}$  where  $\text{R}^{10}$  and  $\text{R}^{11}$  are H or  $\text{C}_1$ - $\text{C}_4$  alkyl. The letter m denotes an integer which is zero or one, and the group Z, when present, is an amino acid or peptide residue, preferred peptide residues being those containing 2 to 20 amino acids.

In certain preferred embodiments, X is of Formula II where  $\text{R}^6$  is H and  $\text{R}^7$  is  $\text{C}_1$ - $\text{C}_{10}$  alkyl, ( $\text{C}_1$ - $\text{C}_8$  cycloalkyl)-( $\text{C}_1$ - $\text{C}_4$  alkyl), ( $\text{C}_1$ - $\text{C}_{10}$  alkylthio)-( $\text{C}_1$ - $\text{C}_{10}$  alkyl), or aryl-( $\text{C}_1$ - $\text{C}_6$  alkyl). In further preferred embodiments,  $\text{R}^6$  and  $\text{R}^7$  are both  $\text{C}_1$ - $\text{C}_{10}$  alkyl.

In further preferred embodiments, X is of Formula II where  $\text{R}^6$  is H,  $\text{R}^7$  is alkyl and  $\text{R}^8$  is arylalkyl. In further preferred embodiments,  $\text{R}^1$  and  $\text{R}^3$  are both CONH,  $\text{R}^2$  and  $\text{R}^4$  are hydrophobic radicals of at least three carbons each,  $\text{R}^5$  is CO, Z is a peptide of between two and ten amino acids, and Y is an amine.

In still further preferred embodiments, X has the formula above wherein R<sup>6</sup> is H, R<sup>7</sup> is pentyl and R<sup>8</sup> is benzyl. Additionally, R<sup>1</sup> and R<sup>3</sup> are both CONH, R<sup>2</sup> and R<sup>4</sup> are alkyl or cycloalkylalkyl of at least three carbons each, R<sup>5</sup> is CO, and Z is a peptide of the formula (AA<sup>i</sup>)<sub>n</sub> in which AA is an amino acid and i is an integer denoting its position downstream from R<sup>5</sup>. An AA<sup>i</sup> at any position may be the same or different from an AA<sup>i</sup> at any other position. AA<sup>1</sup> is preferably Arg, Har, Orn, Lys, Nε,Nε-Dimethyl-Lys, Nε-Acetimidyl-Lys, Nε-Phenylimidyl-Lys, Gln or Asn; AA<sup>2</sup> is preferably Asn, Gln, Arg, Lys, Har, Orn, Nε,Nε-Dimethyl-Lys or Nε-Methyl-Lys; AA<sup>3</sup> when present is Pro, Sar, Gly, Asp or Glu, with n being 3 to 10 and preferably 3 to 6; AA<sup>4</sup>, when n is 4 to 10 or 4 to 6, is preferably Asn, Gln, Gly or Ala; AA<sup>5</sup>, when n is 5 to 10 or 5 to 6, is Asp or Glu; and AA<sup>6</sup>, when n is 6 to 10, is preferably Lys, Arg, Orn and Har; and Y is NH<sub>2</sub>.

The most preferred embodiments are those in which X is represented by Formula II, wherein R<sup>6</sup> is H, R<sup>7</sup> is pentyl and R<sup>8</sup> is benzyl. Additionally, R<sup>1</sup> and R<sup>3</sup> are both CONH, R<sup>2</sup> and R<sup>4</sup> are both cyclohexylmethyl, R<sup>5</sup> is CO, Z is a peptide of the formula (AA<sup>i</sup>)<sub>n</sub> where n is between 2 and 6 and AA<sup>1</sup> is Arg and AA<sup>2</sup> is Lys, Arg or Har, and Y is NH<sub>2</sub>.

In another group of preferred embodiments, X is a hydrophobic radical containing at least one aromatic ring. Additionally, R<sup>1</sup> and R<sup>3</sup> are independently either CONH or CH<sub>2</sub>NH, R<sup>2</sup> and R<sup>4</sup> are hydrophobic radicals of at least four carbons each, R<sup>5</sup> is CO, Z is a peptide of between two and six amino acids and Y is an amine.

Further preferred embodiments within this group are those in which X is aryloxyalkyl, R<sup>1</sup> and R<sup>3</sup> are independently either CONH or CH<sub>2</sub>NH, R<sup>2</sup> and R<sup>4</sup> are independently either isobutyl, benzyl or cyclohexylmethyl, R<sup>5</sup> is CO, Z is a peptide of between two and six amino acids and Y is an amine.

In the most preferred embodiments of this group, X is aryloxyalkyl, R<sup>1</sup> and R<sup>3</sup> are independently either CONH or CH<sub>2</sub>NH, R<sup>2</sup> and R<sup>4</sup> are independently either isobutyl, benzyl or cyclohexylmethyl, R<sup>5</sup> is CO, Z is a peptide of the formula (AA<sup>i</sup>)<sub>n</sub> where n is between 2 and 6 and AA<sup>1</sup> is Arg and AA<sup>2</sup> is Lys, Arg or Har, and Y is NH<sub>2</sub>.

The compounds of the present invention further include those compounds in which any or all amide groups (CONH) which would otherwise be present have been alkylated (for example, CON(Me)) or replaced by suitable isosteres. Examples of isosteres of CONH are —CH<sub>2</sub>NH—, —CH<sub>2</sub>CH<sub>2</sub>—, —CH<sub>2</sub>S—, —CH<sub>2</sub>SO—, —COCH<sub>2</sub>—, —CH(OH)CH<sub>2</sub>— and —CH=CH—, —NHCO—, —SO<sub>2</sub>NH—, —CH<sub>2</sub>O— and 1,5-disubstituted tetrazole.

The compounds of the present invention which terminate with a carboxylic acid further include any pharmaceutically acceptable salts or esters of the acid.

The thrombin receptor antagonists of the present invention may be prepared by solid phase peptide synthesis which is extensively described and used in the art to

prepare peptides. The compounds may also be prepared using liquid phase synthetic peptide methods which are also well known in the art. See, M. Bodanszky and A. Bodanszky, *The Practice of Peptide Synthesis* (1984) and M. Bodanszky, *Principles of Peptide Synthesis* (1984).

5                Synthesis of peptide analogs containing isosteric replacements, following chemical procedures which are known to those of skill in the art, are outlined below.

              Additional aspects of the invention are directed to pharmaceutical compositions containing the compounds of the invention. These compounds are useful for example, in the treatment of myocardial infarction, unstable angina, abrupt closure, 10        restenosis following angioplasty, inflammation and wound healing. The antagonists of the invention may be administered in conventional formulations. One common formulation might include a saline solution buffered to pH 7.4, and suitable for administration by injection. Formulations for bolus administration are also useful, and comprise the selected antagonist with pharmaceutically acceptable excipients such as starch or gum arabic as 15        binding agents. Other typical formulations may be found in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, latest edition.

              Systemic administration of the compounds is typically carried out by injection, preferably by intravenous injection. Alternatively, intramuscular, intraperitoneal or subcutaneous injection may be used. Other forms of systemic administration of the 20        compounds such as transdermal or transmucosal administration are also possible. Oral administration may also be used with properly formulated enteric or encapsulated formulations.

              The dosage used will depend on such factors as the choice of antagonist, the route of administration, the nature of the formulation, the nature of the patient's illness and 25        the judgment of the attending physician. Typically, the dosage will be in the range of 0.1-100  $\mu\text{g/kg}$  of subject. More preferably, the dosage will be in the range of 1-50  $\mu\text{g/kg}$  of subject.

              The following experimental results are offered by way of example and not by way of limitation.

## EXAMPLE 1

Synthesis of (N,N-di-n-pentyl-Phe)-Cha-Cha-Arg-Lys-NH<sub>2</sub>

Starting with 0.5 mmol of p-methylbenzhydrylamine•HCl resin (from Applied Biosystems), the resin was neutralized with diisopropylethyl amine and coupled  
5 with N $\alpha$ -t-BOC-N $\epsilon$ -(2-chloro-CBZ)-L-lysine using N,N-dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole (HOBt) in N-methylpyrrolidinone (NMP) as solvent followed by deprotection with trifluoroacetic acid (TFA) in dichloromethane. Successive couplings and deprotections were performed with Boc-Arg(Tos), Boc-Cha, Boc-Cha and Boc-Phe. Following removal of the Boc group from the Phe residue with the aid of TFA, the resin  
10 was washed to afford the peptide resin trifluoroacetate. To this resin, which was suspended in DMF, 2.5 equivalents of n-valeraldehyde in dimethylformamide (DMF) (containing 1% acetic acid) was added followed by treatment with 2.5 equivalents of NaBH<sub>3</sub>CN for 60 min at room temperature. Aliquots of resin were removed periodically to check for completeness of alkylation by ninhydrin reaction. When the alkylation was  
15 determined to be complete, the resin was washed with DMF, CH<sub>2</sub>Cl<sub>2</sub>, and methanol and dried *in vacuo*. The peptide was cleaved from the resin and the protecting groups were removed by treatment with anhydrous HF containing 10% anisole and 2% methyl ethyl sulfide. The resin/peptide mixture was extracted with 25% acetic acid solution and lyophilized to afford the crude peptide as a white powder. Subsequent purification of the  
20 peptide on a C<sub>18</sub> reversed phase column employing a gradient elution (10-60% CH<sub>3</sub>CN in water containing 0.1% TFA) provided the desired peptide. FAB mass spectrum, calcd. mass 895, observed M+1 896.

## EXAMPLE 2

Synthesis of 2-Phenoxybutyryl-Cha-Cha-Arg-Lys-NH<sub>2</sub>

25                Synthesis of the peptide resin up to Cha-Cha-Arg-Lys-MBHA resin was performed as described in Example 1. Acylation of the peptide resin with ( $\pm$ )2-phenoxybutyric acid was carried out using DCC in NMP with HOBt. The resulting resin was washed and the peptide was cleaved, deprotected and purified using the conditions in Example 1. FAB mass spectrum, calcd. mass 770, observed M+1 771.

## EXAMPLE 3

Synthesis of (N-n-pentyl-Tic)-Cha-Cha-Arg-Lys-NH<sub>2</sub>

Synthesis of the peptide resin to Tic-Cha-Cha-Arg-Lys-MBHA resin was performed as in Example 1, substituting Boc-Tic for Boc-Phe. After removal of the Boc group from the Tic residue, the resin was reductively alkylated with n-valeraldehyde under the conditions of Example 1. The resin was washed and the peptide was cleaved, deprotected and purified using the conditions above. FAB mass spectrum, calcd. mass 837, observed M+1 838.

## EXAMPLE 4

10 Synthesis of Phenyl—CH=C((CH<sub>2</sub>)<sub>5</sub>-CH<sub>3</sub>)-CH<sub>2</sub>-Cha-Cha-Arg-Lys-NH<sub>2</sub>

Synthesis of the peptide resin up to TFA•NH<sub>2</sub>-Cha-Cha-Arg-Lys-MBHA was performed as described in Example 1. The amino group was reductively alkylated using 2.5 equivalents of phenyl-CH=C((CH<sub>2</sub>)<sub>5</sub>-CH<sub>3</sub>)-CHO in DMF with NaBH<sub>3</sub>CN for 2 h at room temperature. The resin was washed and dried and the peptide was cleaved, deprotected and purified using the above conditions. FAB mass spectrum, calcd. mass 803, observed M+1 804.

## EXAMPLE 5

## Assay for Thrombin Receptor Antagonist Activity

The compounds of the present invention may be tested for thrombin receptor antagonist activity by using a platelet aggregation assay. In this assay, washed human platelets are prepared from blood drawn from healthy volunteers who have not ingested any medications for two weeks prior to donation. Blood is drawn into 12.5% (vol/vol) ACD (85 mM sodium citrate, 111 mM dextrose, 71 mM citric acid) containing 0.1% (vol/vol) PGI<sub>2</sub> (0.05 mg/mL PGI<sub>2</sub>, 100 mM Tris, pH 12). Platelet-rich plasma was obtained by centrifugation at 160Xg for 20 minutes. The platelets were pelleted by centrifugation at 760Xg for 10 minutes and resuspended in CGS (13 mM trisodium citrate, 120 mM sodium chloride, 30 mM dextrose, pH 7.0) containing 0.1% (vol/vol) PGI<sub>2</sub>, repelleted and resuspended in Tyrodes buffer (10 mM Hepes, 12 mM sodium bicarbonate, 138 mM sodium chloride, 5.5 mM glucose, 2.9 mM potassium chloride, 1.0 mM calcium chloride, pH 7.4) and stored at 37°C. Approximately 0.4-10 nM α-thrombin is used to stimulate platelet aggregation in control reactions which are monitored by aggregometry using an aggregometer. Candidate antagonists are added to the platelet mixture followed by the addition of thrombin in order to assess their ability to prevent









thrombin-mediated aggregation.

Platelet aggregation can also be measured with washed platelets in 96-well microtiter plates as described in Fratantoni, J.C. *et al.*, *Am. J. Clin. Pathol.* 94:613-617 (1990). The ability of the antagonists to block the thrombin receptor was assessed in this  
5 assay using various concentrations of antagonists. The concentration at which 50% inhibition of platelet aggregation is achieved is defined as  $IC_{50}$ .

The following table lists  $IC_{50}$  values for representative compounds of the invention.

## TEST RESULTS

Compound  
No. \_\_\_\_\_StructureIC<sub>50</sub> (μM)

1		5
2		10
3		10
4		5
5		2.5
6		10
7		5
8		5




15

## TEST RESULTS (Continued)

Compound  
No. \_\_\_\_\_StructureIC<sub>50</sub> (μM)

9



15


10



"

10


11



"

2.5


12



"

20

13




"

5

## TEST RESULTS (Continued)

Compound  
No. \_\_\_\_\_StructureIC<sub>50</sub> (μM)


14



"

5


15



"

10


16



"

10






17



"

15


## TEST RESULTS (Continued)

Compound No.	Structure	IC <sub>50</sub> (μM)
18		5
19		30
20		15
21		10
22		25

## TEST RESULTS (Continued)

Compound  
No. \_\_\_\_\_StructureIC<sub>50</sub> (μM)

23




"



5

24




"



15

25




"



25

26




"



7.5

27




"



5

28










"









30

## TEST RESULTS (Continued)

Compound No.	Structure	IC <sub>50</sub> (μM)
29		>200
30		20
31		>200
32		15
33		5
34		15
35		20


## TEST RESULTS (Continued)

Compound No.	Structure	IC <sub>50</sub> (μM)
36		7.5
37		> 100
38		10
39		8
40		5
41		25

## TEST RESULTS (Continued)


Compound  
No. \_\_\_\_\_StructureIC<sub>50</sub> (μM)

42




2.0

43




15

44




5

45



5

46



15

## TEST RESULTS (Continued)

Compound No.	Structure	$IC_{50}$ ( $\mu M$ )
47		2.5
48		10
49		75
50		100
51		2.5
52		15
53		2.0
54		0.5




## TEST RESULTS (Continued)

Compound No.	Structure	IC <sub>50</sub> (μM)
55		1.0
56		6.0
57		2.0
58		> 100
59		90
60		25

## TEST RESULTS (Continued)

Compound  
No. \_\_\_\_\_StructureIC<sub>50</sub> (μM)


Compounds 61-63 are also within the scope of the present invention, however, no test data was available at the time the application was filed.



The foregoing is offered primarily for purposes of illustration. It will be readily apparent to those skilled in the art that the structures, methods, composition components, synthesis and use conditions, and other parameters of the system described herein may be further modified or substituted in various ways without departing from the spirit and scope of the invention.

## WHAT IS CLAIMED IS:

1. A thrombin receptor antagonist of the formula:



wherein:


$\text{R}^1$  and  $\text{R}^3$  are members independently selected from the group consisting of CONH and isosteres thereof;

$\text{R}^2$  is a member selected from the group consisting of hydrophobic radicals and neutral amino acid side chains;

$\text{R}^4$  is a hydrophobic radical;

$\text{R}^5$  is a member selected from the group consisting of  $\text{CH}_2$ , CO and SO;

X is a member selected from the group consisting of:  
radicals of the formula



wherein:

$\text{R}^6$  and  $\text{R}^7$  are members independently selected from the group consisting of H,  $\text{C}_1$ - $\text{C}_{10}$  alkyl, ( $\text{C}_1$ - $\text{C}_8$  cycloalkyl)-( $\text{C}_1$ - $\text{C}_4$  alkyl), ( $\text{C}_1$ - $\text{C}_{10}$  alkoxy)-( $\text{C}_1$ - $\text{C}_{10}$  alkyl), ( $\text{C}_1$ - $\text{C}_{10}$  alkylthio)-( $\text{C}_1$ - $\text{C}_{10}$  alkyl), aryl-( $\text{C}_1$ - $\text{C}_6$  alkyl), with the proviso that at least one of  $\text{R}^6$  and  $\text{R}^7$  is other than H, and

$\text{R}^8$  is a hydrophobic radical,

arylalkyl, arylalkenyl, aryloxyalkyl, biphenyl, 1,2,3,4-tetrahydronaphthyl, indolylmethyl, quinoliny, isoquinoliny, 1,2,3,4-tetrahydroisoquinoliny, 1,2,3,4-tetrahydroquinoliny, N-alkyl 1,2,3,4-tetrahydroisoquinoliny, N-alkyl 1,2,3,4-tetrahydroquinoliny and N-(cycloalkyl)alkyl-1,2,3,4-tetrahydroisoquinoliny;

Y is a member selected from the group consisting of  $\text{OR}^9$  and  $\text{NR}^{10}\text{R}^{11}$

wherein  $\text{R}^9$ ,  $\text{R}^{10}$  and  $\text{R}^{11}$  are members independently selected from the


group consisting of H, C<sub>1</sub>-C<sub>10</sub> alkyl and a hydrocarbon radical substituted with a basic moiety;

30

Z is a member selected from the group consisting of amin acids and peptides comprising from 2 to 20 amino acids; and m is zero or one.

2. A thrombin receptor antagonist of claim 1 wherein X is 1-phenyloct-1-en-2-yl, 1-phenoxy-1-propyl, 1-(2-naphthyloxy)-1-heptyl, 1-phenoxy-1-pentyl, 1-(1-naphthyloxy)-1-pentyl, biphenyl, 1,2,3,4-tetrahydronaphth-2-yl, indolylmethyl, 2- or 3-quinoliny, or N-pentyl-1,2,3,4-tetrahydroisoquinoliny.

3. A thrombin receptor antagonist of claim 1 wherein X is a radical of the formula




wherein:

5

R<sup>6</sup> and R<sup>7</sup> are members independently selected from the group consisting of H, C<sub>1</sub>-C<sub>10</sub> alkyl, (C<sub>1</sub>-C<sub>8</sub> cycloalkyl)-(C<sub>1</sub>-C<sub>4</sub> alkyl), (C<sub>1</sub>-C<sub>10</sub> alkoxy)-(C<sub>1</sub>-C<sub>10</sub> alkyl), (C<sub>1</sub>-C<sub>10</sub> alkylthio)-(C<sub>1</sub>-C<sub>10</sub> alkyl), aryl-(C<sub>1</sub>-C<sub>6</sub> alkyl), with the proviso that at least one of R<sup>6</sup> and R<sup>7</sup> is other than H; and R<sup>8</sup> is benzyl or phenethyl.

4. A thrombin receptor antagonist of claim 1 wherein X is a radical of the formula




wherein:

5

R<sup>6</sup> is H and R<sup>7</sup> is a member selected from the group consisting of C<sub>1</sub>-C<sub>10</sub>

alkyl, (C<sub>1</sub>-C<sub>8</sub> cycloalkyl)-(C<sub>1</sub>-C<sub>4</sub> alkyl), (C<sub>1</sub>-C<sub>10</sub> alkoxy)-(C<sub>1</sub>-C<sub>10</sub> alkyl), (C<sub>1</sub>-C<sub>10</sub> alkylthio)-(C<sub>1</sub>-C<sub>10</sub> alkyl) and aryl-(C<sub>1</sub>-C<sub>6</sub> alkyl); and R<sup>8</sup> is benzyl or phenethyl.

5. A thrombin receptor antagonist of claim 1 wherein X is a radical of the formula



wherein:

- 5 R<sup>6</sup> and R<sup>7</sup> are both C<sub>1</sub>-C<sub>10</sub> alkyl; and  
R<sup>8</sup> is benzyl or phenethyl.


6. A thrombin receptor antagonist of claim 1 wherein R<sup>2</sup> is cyclohexylmethyl and R<sup>4</sup> is a member selected from the group consisting of phenyl, *t*-butyl, isopropyl, isobutyl, cyclohexylmethyl, benzyl, 4-hydroxybenzyl, 2-naphthylmethyl, 1-naphthylmethyl, 2-thienylmethyl, methylthioethyl, indolylmethyl, and substituted benzyl.

7. A thrombin receptor antagonist of claim 1 wherein R<sup>2</sup> is a member selected from the group consisting of phenyl, *t*-butyl, isopropyl, isobutyl, cyclohexylmethyl, benzyl, 4-hydroxybenzyl, 2-naphthylmethyl, 1-naphthylmethyl, 2-thienylmethyl, methylthioethyl, indolylmethyl, and substituted benzyl and R<sup>4</sup> is  
5 cyclohexylmethyl.

8. A thrombin receptor antagonist of claim 1 wherein Z is a peptide of the formula (AA)<sup>i</sup><sub>n</sub>, wherein AA represents an amino acid residue; i is an integer denoting the position downstream from R<sup>5</sup>; and n is an integer of from 2 to 20; such that amino acid residues at any said position may be the same as or different from amino acid residues at  
5 any other said position.

9. A thrombin receptor antagonist of claim 1 wherein Y is NR<sup>10</sup>R<sup>11</sup>, in which R<sup>10</sup> and R<sup>11</sup> are members independently selected from the group consisting of H and C<sub>1</sub>-C<sub>4</sub> alkyl.

10. A method to treat conditions mediated by unwanted thrombin receptor activity which method comprises administering to a subject in need of such treatment an effective amount of a compound of formula:



5 wherein:


$R^1$  and  $R^3$  are members independently selected from the group consisting of CONH and isosteres thereof;

$R^2$  is a member selected from the group consisting of hydrophobic radicals and neutral amino acid side chains;

10  $R^4$  is a hydrophobic radical;

$R^5$  is a member selected from the group consisting of  $CH_2$ , CO and SO;

X is a member selected from the group consisting of:  
radicals of the formula



15

wherein:

$R^6$  and  $R^7$  are members independently selected from the group consisting of H,  $C_1$ - $C_{10}$  alkyl, ( $C_1$ - $C_8$  cycloalkyl)-( $C_1$ - $C_4$  alkyl), ( $C_1$ - $C_{10}$  alkoxy)-( $C_1$ - $C_{10}$  alkyl), ( $C_1$ - $C_{10}$  alkylthio)-( $C_1$ - $C_{10}$  alkyl), aryl-( $C_1$ - $C_6$  alkyl), with the proviso that at least one of  $R^6$  and  $R^7$  is other than H, and

20

$R^8$  is a hydrophobic radical,  
arylalkyl, arylalkenyl, aryloxyalkyl, biphenyl, 1,2,3,4-tetrahydronaphthyl, indolylmethyl, quinoliny, isoquinoliny, 1,2,3,4-tetrahydroisoquinoliny, 1,2,3,4-tetrahydroquinoliny, N-alkyl 1,2,3,4-tetrahydroisoquinoliny, N-(cycloalkyl)alkyl 1,2,3,4-tetrahydroisoquinoliny, and N-alkyl 1,2,3,4-tetrahydroquinoliny;

25

Y is a member selected from the group consisting of  $OR^9$  and  $NR^{10}R^{11}$

wherein  $R^9$ ,  $R^{10}$  and  $R^{11}$  are members independently selected from the

30 group consisting of H, C<sub>1</sub>-C<sub>10</sub> alkyl, and a hydrocarbon radical  
substituted with a basic moiety;

Z is a member selected from the group consisting of amino acids and  
peptides comprising from 2 to 20 amino acids; and

m is zero or one;

35 or a pharmaceutical composition thereof.

## INTERNATIONAL SEARCH REPORT

Intern 11 Application No

PCT/US 93/06428

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C07K5/00 C07K7/00 A61K37/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF CLINICAL INVESTIGATION vol. 89, no. 4, April 1992 pages 1350 - 1353 D.T. HUNG ET AL 'Cloned Platelet Thrombin Receptor Is Necessary for Thrombin-induced Platelet Activation' see page 1350, right column, paragraph 3 ---	1,8,10
P,X	WO,A,92 14750 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 3 September 1992 see page 15, line 11 - page 23, line 2; claims 10-21,26,27; examples 4,6 ---	1-10
E	WO,A,93 18141 (BIOGEN, INC.) 16 September 1993 see claims; examples --- -/--	1,8,10

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

16 November 1993

Date of mailing of the international search report

10 -12- 1993

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

FUHR, C



## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>JOURNAL OF BIOLOGICAL CHEMISTRY vol. 268, no. 19 , 5 July 1993 , BALTIMORE, MD US pages 14322 - 14328 U.B. RASMUSSEN ET AL. 'A Peptide Ligand of the Human Thrombin Receptor Antagonizes alpha-Thrombin and Partially Activates Platelets' see Discussion on pages 14326-14327</p>	1,8,10
A	<p>BIOCHEMICAL PHARMACOLOGY vol. 37, no. 12 , 1988 , OXFORD, UK pages 2417 - 2426 E.M. RUDA ET AL. 'Identification of Small Peptide Analogues having Agonist and Antagonist Activity at the Platelet Thrombin Receptor' see Discussion on pages 2423-2425 see figure 1</p>	1-10
P,A	<p>PHARMACOLOGICAL RESEARCH vol. 27, no. 1 , January 1993 pages 1 - 19 R. DE CATERIAN AND R. SICARI 'CELLULAR EFFECTS OF THROMBIN: PHARMACOLOGY OF THE RECEPTORS IN VARIOUS CELL TYPES AND POSSIBLE DEVELOPMENT OF RECEPTOR ANTAGONISTS' see page 10, paragraph 4 - page 11, paragraph 2</p>	1-10

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/06428

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 1-9  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
See annex
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

In view of the extremely large number of compounds falling under claims 1-9, the ISA considers that it is not economically reasonable to draw up a search report covering all compounds "per se" (see Article 17.2 aii). The search has therefore been limited to the examples given in the description and extended to compounds having the alleged thrombin receptor antagonistic activity.

Remark : Although claim 10 is directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 93/06428

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9214750	03-09-92	US-A- 5256766 AU-A- 1456892	26-10-93 15-09-92
WO-A-9318141	16-09-93	NONE	